Read the full article here: link
]]>Read the full article here: link
]]>In parallel, TRI has launched Scan&Smile™ in 15 Minutes, integrating a new AI-enabled crown designer (TRI® AI Crown) into its digital workflow. The platform is designed to allow clinicians to deliver a highly aesthetic provisional restoration directly on the implant within 15 minutes, supporting an “immediate” fully digital workflow. TRI positions this as a differentiated “world-first” type offering because the workflow is built on the no-abutment matrix® concept, enabling restoration planning and chairside execution directly at implant level rather than via conventional abutment-based steps.
Taken together, the two launches extend TRI’s proposition beyond hardware into a tightly integrated implant plus digital application ecosystem, improving speed, simplicity, and standardisation of implant restorations, while strengthening TRI’s differentiation in the US market through the X-Force availability and the AI-enabled workflow.
]]>Methods such as statistical experimental design (DoE) and a rapid prototyping approach are used to close data gaps. This is based on AMW’s 15 years of research experience with GnRH agonists for the treatment of hormone-dependent tumours. With this data-driven approach, AMW aims to accelerate the development of new formulations and position itself as a pioneer in a previously underserved area of drug development.
Click here for the article: link
]]>The Series B round was led by Innovation Industries, with participation from Invest-NL and the EIC Fund, alongside existing investors including SHS Capital. The company states that the capital will support completion of its clinical programme and the transition to commercial readiness.
A key focus is progress of RECLAIM, Salvia’s multi-centre, double-blind, sham-controlled study in chronic migraine patients, intended to generate the clinical evidence required for regulatory approvals and adoption in routine care. In parallel, Salvia plans to advance regulatory submissions, including securing FDA market authorisation in the US and progressing approvals in Europe and Australia.
Salvia also highlights that MySalvia Therapy has received FDA Breakthrough Device designation, underlining its potential to address an important unmet need in chronic migraine. The company notes potential longer-term applicability of the technology in other headache disorders such as cluster headache, although the therapy remains under evaluation and is not yet approved for commercial use.
Read the full article here: link
]]>Healthcare Specialist SHS Capital agreed to sell its portfolio company PathoQuest, a specialist in NGS-based quality control assays for biopharmaceuticals, to the strategic buyer Charles River Laboratories, a leading global provider of products and services that support drug discovery and non-clinical development.
Founded in Paris, PathoQuest has established itself as a reference player in NGS-based viral safety and genetic characterisation testing for biopharmaceuticals. Its proprietary iDTECT® platform enables highly sensitive, comprehensive and GMP-compliant quality control, addressing the growing complexity of biologic modalities and increasing regulatory expectations.
Over recent years, the company has further developed its technology platform, strengthened operational structures and expanded its commercial focus towards late-stage and commercial biopharmaceuticals where GMP compliance is critical. During this period, PathoQuest also broadened its international footprint, including the establishment and certification of a second GMP-compliant site in the United States, enabling it to better serve global biotech and biopharma customers.
The strategic combination with Charles River builds on a long-standing partnership and reflects the increasing role of NGS-based methods in biopharmaceutical safety testing. By combining PathoQuest’s specialised NGS expertise with Charles River’s global reach, regulatory capabilities and customer base, the transaction aims to further scale advanced, data-rich and animal-free testing approaches across the lifecycle of biopharmaceuticals.
“PathoQuest has continuously evolved its technology, organisation and international presence to meet the growing demands of the biopharmaceutical market,” said Jean-François Brepson, CEO of PathoQuest. “Becoming part of Charles River represents a strong strategic step to accelerate our mission and make NGS-based biosafety testing the global standard. We thank SHS for supporting us over the years to become the global partner of choice in our industry.”
“PathoQuest’s NGS-based capabilities are highly complementary to Charles River’s biopharmaceutical service portfolio,” said Kerstin Dolph, Senior Vice President Manufacturing at Charles River Laboratories. “As biologic modalities become more complex, our clients increasingly require comprehensive, highly sensitive and scalable quality control solutions. This acquisition strengthens our ability to support customers globally and to help advance modern, data-driven and animal-free testing approaches across the lifecycle of biopharmaceuticals.”
“This transaction reflects the successful development of PathoQuest over recent years,” said Sascha Alilovic, Managing Partner at SHS Capital. “Together with our co-investors, SHS supported the company in strengthening its operational foundation, expanding into the US with GMP-compliant capabilities and sharpening its commercial positioning. Based on the successful strategy execution, PathoQuest was able to quadruple its revenues since SHS invested. The combination with Charles River provides a strong platform for the next phase of growth.”
About PathoQuest:
With over 20 peer-reviewed publications on NGS applications, PathoQuest is a leading expert in the application of Good Manufacturing Practices (GMP)-compliant Next Generation Sequencing (NGS)-based biosafety testing. PathoQuest offers biopharmaceutical companies a game-changing genomic approach to ensuring the safety of biologics such as cell and gene therapy products, vaccines, and recombinant proteins, ultimately enabling a reduction in the time to market for these innovative treatments. PathoQuest’s technology combines NGS platforms with proprietary sample preparation and data analysis processes to bring novel solutions to the industry. PathoQuest, headquartered in Paris, France, with a US based site in Wayne (PA) has worked with over 100 of the leading biopharmaceutical companies globally.
About SHS Capital:
SHS Capital is a private equity provider founded in 1993 that invests in healthcare companies in Europe. The focus of the investments is on expansion financing, shareholder changes and succession situations. “Building European Healthcare Champions” is the investment philosophy according to which SHS finances and develops portfolio companies. The Tübingen-based investor takes both minority and majority stakes. The national and international investors in SHS funds include pension funds, funds of funds, foundations, family offices, strategic investors, entrepreneurs and the SHS management team. The equity or equity-like investment of the AIF is up to € 50 million. Volumes in excess of this can be realised with a network of co-investors. In its investment decisions, SHS attaches great importance to the consideration of ESG aspects and has therefore committed itself to the guidelines of the UN PRI. SHS is currently investing from its sixth fund, which was launched in 2022 and has a volume of ca. € 270 million. More information at http://www.shs-capital.eu
Are you interested in receiving regular updates about SHS? Subscribe to our Newsletter and follow us on LinkedIn.
PR contact:
Regine Hujer
SHS Gesellschaft für Beteiligungsmanagement mbH
Bismarckstrasse 12
72072 Tuebingen
tuebingen@shs-capital.eu
Tübingen / Kaltenkirchen / Illmensee, 17 December 2025
SHS Capital invests through its SHS VI fund in a consortium of four German medical technology companies focused on endoscopy systems, comprising EMOS Technology, InnoView, ILO electronic and Micon.
The Endoscopy Group develops and manufactures high-quality, reusable flexible, rigid and semi-flexible endoscopes as well as camera and light systems and insufflators. The products are used in a wide range of minimally invasive procedures and diagnostics, including ENT, urology, gynaecology, orthopaedics, laparoscopy, bronchoscopy and veterinary medicine. All essential steps in the value chain, from optics manufacturing through to final assembly, are carried out at modern facilities in Germany. The group is positioned primarily as a supplier to national and international OEM customers and distributors.
Under the leadership of founder and managing director Frank Spillner, the group was established as the endoscopy arm of G. Heinemann Medizintechnik GmbH. Through the acquisition of the endoscopy and imaging specialists ILO electronic, Micon Medizintechnik, EMOS Technology and InnoView, a platform with a broad product portfolio has been created. With the entry of SHS, the group is now set to grow even closer together and further strengthen its position as an integrated platform.
SHS intends to accompany the Endoscopy Group as a growth partner in the coming years and support its development through growth initiatives focused on expanding relationships with existing customers, further internationalisation and the development of additional products.
“With SHS, we have found a long-term-oriented partner with proven MedTech expertise who understands our business model and shares our vision of an integrated endoscopy platform,” explains Frank Spillner. “The investment enables us to invest in innovation, manufacturing and international market development while at the same time implementing a structured succession solution for the endoscopy business that actively preserves our DNA as a reliable, quality-leading ‘Made in Germany’ manufacturer.”
“The Endoscopy Group is one of the few European manufacturers covering the entire spectrum of endoscopes, imaging and accessories with a high degree of in-house manufacturing, positioning itself as a strategic partner for OEMs and distributors worldwide,” says Tobias Fuchs, Senior Investment Manager at SHS Capital. “On this basis, we aim develop a leading European endoscopy platform together with the ambitious management team and further scale the international business.”
About the Endoscopy Group
The Endoscopy Group consists of EMOS Technology GmbH, InnoView GmbH, ILO electronic GmbH and Micon Medizintechnik GmbH. The group develops and manufactures high-quality, reusable flexible, rigid and semi-flexible endoscopes as well as camera and light systems and insufflators for a broad range of minimally invasive procedures, including ENT, urology, gynaecology, orthopaedics, laparoscopy, bronchoscopy and veterinary medicine. All key value creation steps take place at modern sites in Germany. The group primarily supplies international OEM customers and distributors and is distinguished by strong technical expertise, continuous product innovation and very high customer loyalty. The group’s customers are located in Europe, North America, Latin America and Asia.
About SHS Capital
SHS Capital is a private equity provider founded in 1993 that invests in healthcare companies in Europe. The focus of the investments is on expansion financing, shareholder changes and succession situations. “Building European Healthcare Champions” is the investment philosophy according to which SHS finances and develops portfolio companies. The Tübingen-based investor takes both minority and majority stakes. The national and international investors in SHS funds include pension funds, funds of funds, foundations, family offices, strategic investors, entrepreneurs and the SHS management team. The equity or equity-like investment of the AIF is up to € 50 million. Volumes in excess of this can be realised with a network of co-investors. In its investment decisions, SHS attaches great importance to the consideration of ESG aspects and has therefore committed itself to the guidelines of the UN PRI. SHS is currently investing from its sixth fund, which was launched in 2022 and has a volume of ca. € 270 million.
More information at: www.shs-capital.eu
Are you interested in receiving regular updates about SHS? Subscribe to our Newsletter and follow us on LinkedIn
PR contact:
Regine Hujer
SHS Gesellschaft für Beteiligungsmanagement mbH
Bismarckstrasse 12
72072 Tuebingen
tuebingen@shs-capital.eu
- Curatec is a specialist in medical electrical stimulation and rehabilitation devices based in North Rhine-Westphalia, Germany.
- The transaction expands MTR’s existing product portfolio, strengthens its market position in electrical stimulation with a particular focus on neurological applications, and secures Curatec’s succession.
Tübingen, 25 November 2025
SHS Capital, together with its portfolio company MTR, has acquired Curatec Services GmbH, an established provider of innovative electrical stimulation devices. The aim of the transaction is to secure Curatec’s proven expertise and product range for the long term, expand it within the MTR platform, and ensure that patients throughout Germany receive high-quality, innovative solutions in neurology and uro-gynaecology.
Curatec Services GmbH is a specialised provider of medical electrical stimulation and rehabilitation devices for home use. The company focuses on therapies in neurology, uro-gynaecology, and orthopaedics. With more than 25 years of experience and a highly dedicated team, Curatec has established itself as an innovative niche provider known for high-quality medical devices and strong, patient-centred service. Thanks to established relationships with rehabilitation clinics, hospitals, specialist practices, and homecare providers, as well as trusted cooperations with statutory health insurers, Curatec enjoys an excellent reputation as a pioneer in electrotherapy.
With this transaction, MTR and SHS continue their joint strategy to improve patient care through high-quality, technology-supported therapy solutions. Curatec expands the existing MTR portfolio with specialised solutions for neurological applications, functional electrical stimulation (FES), and incontinence therapy. Curatec’s strong regional presence in North Rhine-Westphalia also enhances MTR’s geographic footprint and opens new commercial opportunities in western Germany. The combined product portfolios and the integrated sales and service networks create significant synergies that will further improve patient access to modern therapy solutions. MTR and SHS intend to preserve Curatec’s proven technology platform and existing customer network while systematically expanding the offering in advanced electrotherapy.
“We are pleased that SHS and MTR will continue and further develop our business. Preserving the trust in the quality of our work that we built over many years and ensuring that patients who urgently rely on our products continue to benefit from them, has been our priority,” says Curatec Managing Director Rainer Eckert.
“By acquiring Curatec, we are strengthening our combined market presence and will have an even more comprehensive product portfolio in electrical stimulation therapy. This partnership provides an excellent foundation for further growth and the highest standards in patient care,” comments MTR Managing Director Andreas Markschies.
“This acquisition exemplifies the SHS approach of guiding innovative medical technology companies into the next generation, creating sustainable succession solutions, and safeguarding patient care over the long term. Curatec is a company that ideally complements MTR in both product portfolio and regional footprint,” explains SHS Senior Investment Manager Tobias Fuchs.
About SHS Capital
SHS Capital is a private equity provider founded in 1993 that invests in healthcare companies in Europe. The focus of the investments is on expansion financing, shareholder changes and succession situations. “Building European Healthcare Champions” is the investment philosophy according to which SHS finances and develops portfolio companies. The Tübingen-based investor takes both minority and majority stakes. The national and international investors in SHS funds include pension funds, funds of funds, foundations, family offices, strategic investors, entrepreneurs and the SHS management team. The equity or equity-like investment of the AIF is up to € 50 million. Volumes in excess of this can be realised with a network of co-investors. In its investment decisions, SHS attaches great importance to the consideration of ESG aspects and has therefore committed itself to the guidelines of the UN PRI. SHS is currently investing from its sixth fund, which was launched in 2022 and has a volume of ca. € 270 million.
More information at: http://www.shs-capital.eu
Are you interested in receiving regular updates about SHS? Subscribe to our Newsletter
and follow us on LinkedIn
PR contact:
Regine Hujer
SHS Gesellschaft für Beteiligungsmanagement mbH
Bismarckstrasse 12
72072 Tuebingen
tuebingen@shs-capital.eu
As SHS Partner Cornelius Maas explains, our ambition is to help build an even stronger MedTech group. With rising market complexity, we see significant potential for expanding the group and are open to partnering with more companies on this journey.
If you’d like to learn more or explore opportunities, feel free to reach out!
]]>TBI is particularly important in patient groups such as people with diabetes, where conventional ankle-brachial index (ABI) measurements are unreliable. Despite its clinical benefits, TBI has so far been used mainly in secondary care, which can lead to delays in diagnosis.
These results underscore the importance of portable TBI devices such as the MESI mTABLET TBI for clinical decision-making in primary care. Thanks to its ease of use, high accuracy and patient-friendly design, the device can make an important contribution to improving the care of PAD patients, especially where access to specialised procedures is limited.
]]>